Merz Aesthetics, the world’s largest dedicated medical aesthetics business, has announced  the commercial launch of Radiesse (+) lidocaine injectable implant for deep injection (subdermal and/or supraperiosteal) for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over the age of 21. Radiesse injectables represent the first and only calcium hydroxylapatite (CaHA) portfolio in the U.S., and Radiesse (+) is the first and only U.S. Food and Drug Administration (FDA)-approved injectable treatment for jawline contour improvement. The FDA approved the supplemental Premarket Approval Application (sPMA) in September 2021.
Read more at Business Wire >>